AQST DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR RIGHTS COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 4 Deadline in Securities Class Action – AQST

Rosen Law Firm is encouraging investors who suffered losses in securities class action lawsuits against Aquestive Therapeutics, Babcock & Wilcox Enterprises, and Snowflake Inc. to secure legal counsel before upcoming deadlines. The firm is seeking lead plaintiffs for cases involving alleged false statements and disclosure failures.

This article was sourced from GlobeNewswire Inc. and normalized from Massive.com's /v2/reference/news feed for the site.

Publisher: GlobeNewswire Inc.

Author: Rosen Law Firm

Categories: Regulation, Legal, Healthcare, Equities

Tickers: AQST, BW, BWNB, BWPA, SNOW

Sentiment: Negative — Company is subject to securities class action lawsuit alleging false/misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues with sublingual film packaging and administration. Company is subject to an ongoing securities class action lawsuit, though specific allegations are not detailed in the provided excerpt.

Keywords: securities class action, investor losses, lead plaintiff deadline, false statements, disclosure failures, contingency fee

Insights:

• AQST: Negative: Company is subject to securities class action lawsuit alleging false/misleading statements regarding its New Drug Application for Anaphylm, specifically concealing human factors issues with sublingual film packaging and administration.
• BW: Negative: Company is subject to an ongoing securities class action lawsuit, though specific allegations are not detailed in the provided excerpt.
• BWNB: Negative: Company is subject to an ongoing securities class action lawsuit, though specific allegations are not detailed in the provided excerpt.

Read the full article at the source